ALNYLAM PHARMACEUTICALS INC (ALNY) Stock Balance Sheet
NASDAQ:ALNY • US02043Q1076
Current stock price
333.39 USD
-6.02 (-1.77%)
At close:
333.39 USD
0 (0%)
After Hours:
| 2025 (2025-12-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 1.66B | 966.43M | 812.69M | 866.40M | 820.00M | |||
| Marketable Securities | 1.25B | 1.73B | 1.63B | 1.33B | 1.62B | |||
| Receivables | 777.57M | 405.31M | 327.79M | 238.00M | 198.60M | |||
| Inventories | 82.72M | 78.51M | 89.15M | 129.00M | 86.40M | |||
| Other Current Assets | 281.89M | 116.96M | 126.38M | 132.90M | 88.10M | |||
| Total Current Assets | 4.05B | 3.30B | 2.98B | 2.69B | 2.81B | |||
| Non-Current Assets | ||||||||
| PPE Net | 708.06M | 693.93M | 725.79M | 738.60M | 733.60M | |||
| Investments And Advances | N/A | N/A | N/A | N/A | N/A | |||
| Other Non-Current Assets | 207.61M | 250.77M | 121.39M | 115.50M | 101.10M | |||
| Total Non-Current Assets | 915.67M | 944.70M | 847.18M | 854.20M | 834.70M | |||
| TOTAL ASSETS | 4.97B | 4.24B | 3.83B | 3.55B | 3.64B | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 220.07M | 113.02M | 54.99M | N/A | N/A | |||
| Accrued Expenses | 1.13B | 929.36M | 754.52M | 587.40M | 435.70M | |||
| Accounts Payable | 115.72M | 88.42M | 55.52M | 98.10M | 73.40M | |||
| Other Current Liabilities | 4.84M | 55.48M | 102.75M | 82.40M | 186.60M | |||
| Total Current Liabilities | 1.47B | 1.19B | 967.79M | 767.90M | 695.70M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 2.48B | 2.36B | 2.34B | 1.02B | 675.70M | |||
| Other Non-Current Liabilities | 232.68M | 627.65M | 739.71M | 1.92B | 1.68B | |||
| Total Non-Current Liabilities | 2.71B | 2.99B | 3.08B | 2.94B | 2.36B | |||
| TOTAL LIABILITIES | 4.18B | 4.17B | 4.05B | 3.70B | 3.06B | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -6.70B | -7.29B | -7.01B | -6.57B | -5.44B | |||
| Additional Paid In Capital | 7.51B | 7.39B | 6.81B | 6.45B | 6.06B | |||
| Common Shares | 1.32M | 1.29M | 1.26M | 1.20M | 1.20M | |||
| Other Shareholders' Equity | 9.34M | -3.27M | 7.87M | -2.40M | 1.20M | |||
| Shares Outstanding | 132.38M | 129.29M | 125.79M | 123.90M | 120.20M | |||
| Tangible Book Value per Share | 5.96 | 0.52 | -1.75 | -1.28 | 4.89 | |||
| Total Shareholders' Equity | 789.18M | 67.09M | -220.64M | -158.20M | 588.20M | |||
| TOTAL LIABILITIES AND EQUITY | 4.97B | 4.24B | 3.83B | 3.55B | 3.64B | |||
| Statistics | ||||||||
| Debt/Equity | 3.14 | 35.16 | -10.62 | -6.43 | 1.15 | |||
| Current Ratio | 2.76 | 2.78 | 3.08 | 3.51 | 4.04 | |||
| Return On Assets (ROA) | 6.32% | -6.56% | -11.49% | -31.90% | -23.41% | |||
| Return On Equity (ROE) | 39.76% | -414.62% | N/A | N/A | -144.98% | |||
| Return On Invested Capital (ROIC) | 11.32% | N/A | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash (ROICexc) | 66.99% | N/A | N/A | N/A | N/A | |||
| Return On Invested Capital Ex Cash + Goodwill (ROICexgc) | 66.99% | N/A | N/A | N/A | N/A | |||
All data in USD , ROIC based on taxRate of 0.21